In this randomized clinical trial including 161 patients with untreated EGFR-mutant NSCLC brain metastases, gefitinib plus chemotherapy significantly improved intracranial progression-free survival, overall progression-free survival, and overall survival than gefitinib alone, with manageable adverse events. This evidence concerns the gene EGFR and non-small cell lung carcinoma.